Stephan Mathas
Overview
Explore the profile of Stephan Mathas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1807
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lopez C, Schleussner N, Bernhart S, Kleinheinz K, Sungalee S, Sczakiel H, et al.
Haematologica
. 2022 May;
108(2):543-554.
PMID: 35522148
Histone methylation-modifiers, such as EZH2 and KMT2D, are recurrently altered in B-cell lymphomas. To comprehensively describe the landscape of alterations affecting genes encoding histone methylation-modifiers in lymphomagenesis we investigated whole...
12.
Jacob A, Kaul H, Fuchs M, Gillessen S, Kreissl S, Pluetschow A, et al.
Infection
. 2022 Feb;
50(4):925-932.
PMID: 35182355
Purpose: Evidence on the effect of self-protection via social distancing and wearing face-masks on infections during chemotherapy is currently not available. We asked if the occurrence of acute infections during...
13.
Wurster K, Costanza M, Kreher S, Glaser S, Lamprecht B, Schleussner N, et al.
Cancers (Basel)
. 2021 Oct;
13(19).
PMID: 34638496
In 50-60% of cases, systemic anaplastic large cell lymphoma (ALCL) is characterized by the t(2;5)(p23;q35) or one of its variants, considered to be causative for anaplastic lymphoma kinase (ALK)-positive (ALK)...
14.
Liang H, Costanza M, Prutsch N, Zimmerman M, Gurnhofer E, Montes-Mojarro I, et al.
Nat Commun
. 2021 Sep;
12(1):5577.
PMID: 34552066
Anaplastic large cell lymphoma (ALCL), an aggressive CD30-positive T-cell lymphoma, comprises systemic anaplastic lymphoma kinase (ALK)-positive, and ALK-negative, primary cutaneous and breast implant-associated ALCL. Prognosis of some ALCL subgroups is...
15.
Denker S, Bittner A, Frick M, Kase J, Hoffmann J, Trenker C, et al.
Leuk Lymphoma
. 2021 Aug;
63(1):84-92.
PMID: 34414850
Diffuse large-cell B-cell lymphoma (DLBCL) is the most common lymphoid malignancy. About 30-40% of the patients will not be cured by standard Rituximab (R)-CHOP-like immune-chemotherapy, and many of them experience...
16.
Damaschin C, Goergen H, Kreissl S, Plutschow A, Breywisch F, Mathas S, et al.
Leukemia
. 2021 Aug;
36(2):580-582.
PMID: 34408266
No abstract available.
17.
Obenaus M, Schildgen O, Schurmann D, von Brunneck A, Janz M, Keller U, et al.
ERJ Open Res
. 2021 Apr;
7(2).
PMID: 33855064
https://bit.ly/3epiMyO.
18.
Reinke S, Brockelmann P, Iaccarino I, Garcia-Marquez M, Borchmann S, Jochims F, et al.
Blood
. 2020 Oct;
136(25):2851-2863.
PMID: 33113552
Classic Hodgkin lymphoma (cHL) is the cancer type most susceptible to antibodies targeting programmed cell death protein 1 (PD1) and is characterized by scarce Hodgkin and Reed-Sternberg cells (HRSCs), perpetuating...
19.
Brockelmann P, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth T, et al.
JAMA Oncol
. 2020 May;
6(6):872-880.
PMID: 32352505
Importance: In early-stage unfavorable classic Hodgkin lymphoma (cHL), conventional therapy induces high cure rates but also relevant acute and long-term toxic effects. Nivolumab is well tolerated and highly effective in...
20.
von Hoff L, Kargel E, Franke V, McShane E, Schulz-Beiss K, Patone G, et al.
Blood
. 2019 Jan;
133(13):1489-1494.
PMID: 30696620
Persistent NF-κB activation is a hallmark of the malignant Hodgkin/Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL). Genomic lesions, Epstein-Barr virus infection, soluble factors, and tumor-microenvironment interactions contribute to this...